VTRS Viatris
Shrinking but cash-rich generics giant; GAAP losses hide a fairly priced, levered cash machine.
The story
Viatris is a scaled global generics and off-patent branded drug company formed from Mylan and Upjohn. It is a mature, cash-generative business whose moat is manufacturing scale, regulatory know-how and a broad portfolio across 165 markets, not pricing power. Revenue has been shrinking through divestitures and generic price erosion. GAAP margins are distorted by large goodwill impairments and acquisition amortization; underlying cash operating margins remain in the high teens to low 20s. Its stated turnaround depends on a small specialty and pipeline push (WAKIX in Japan, complex generics such as a generic Wegovy) and on paying down debt.
The reported -22% margin reflects non-cash impairments. Normalizing to about 17% (excluding impairments but charging a realistic share of amortization as a proxy for reinvestment) matches the roughly 8x EV/EBITDA the market is paying. Incremental sales-to-capital is set well above the goodwill-inflated 0.51, since growth comes from complex generics and in-licensed products, not from buying whole companies. A 5% failure probability reflects $13B of net debt against a shrinking top line.
Value drivers
| Revenue growth (Y1) | -1.5% |
| Terminal growth | 0.5% |
| Forecast horizon | 6y |
| Target operating margin | 17.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.40 |
| Beta | 0.95 |
| Failure probability | 5.0% |
| Cost of capital (WACC) | 7.7% |
| Terminal WACC | 7.9% |
Valuation bridge
| PV of explicit FCFF | 7.04B |
| PV of terminal value | 15.69B |
| Equity value | 9.16B |
| ÷ shares → per share | $7.98 |
News
neutral +0.10 · 8 articles
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
- Is Viatris Stock Outperforming the S&P 500?
- Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
- 3 US Stocks That Could Gain If Buyers Shift Away From India
- Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
- 3 Healthcare Stocks That Fall Short
- Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
- Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 14.52B | -1.5% | 4.8% | 555.32M | 0 | 555.32M | 515.46M |
| 2 | 14.36B | -1.1% | 10.9% | 1.24B | 0 | 1.24B | 1.07B |
| 3 | 14.26B | -0.7% | 17.0% | 1.91B | 0 | 1.91B | 1.53B |
| 4 | 14.21B | -0.3% | 17.0% | 1.91B | 0 | 1.91B | 1.42B |
| 5 | 14.23B | 0.1% | 17.0% | 1.91B | 10.15M | 1.90B | 1.31B |
| 6 | 14.30B | 0.5% | 17.0% | 1.92B | 50.81M | 1.87B | 1.20B |
Key risks
- Generic price erosion, especially in the US, outpaces new launches and revenue keeps shrinking
- Leverage of about 3x EBITDA constrains flexibility, and more impairments signal value destruction
- Manufacturing and FDA compliance issues (such as warning letters at Indian plants) disrupt supply
Catalysts
- Launching complex generics, such as a generic semaglutide if Viatris wins the Novo patent dispute
- Steady debt paydown and buybacks funded by about $2B+ of free cash flow